Index

351 products, 14–15
361 products, 14

AAMI (Association for the Advancement of Medical Instrumentation), 130, 259
AATB see American Association of Tissue Banks (AATB)
abdominoplasty skin, 218, 219
ABO compatibility, 278, 280
acceptance criteria, 133–4, 139, 140, 141, 151
additives see cryoprotectant additives (CPAs)
Advance Tissue Process (ATP), 260
advanced therapy medicinal products (ATMP), 10, 11–12, 275, 276–7
adverse events/errors, 295–6, 305–7
age of donors, 154, 255, 277
Agência Nacional de Vigilância Sanitária (ANVISA, Brazil), 7, 8
agitation/shaking methods, 92, 93, 94
AHCTA (Alliance for Harmonization of Cellular Therapy Accreditation), 168
airborne particles
contamination control, 108–12, 114, 115, 117
ISO 14644-4641, 296
musculoskeletal tissue, 257
open/closed processing, 274
alcohol soaks, 87, 93, 95
alemtuzumab, 284, 285
ALG (anti-lymphocyte globulin), 284
Alliance for Harmonization of Cellular Therapy Accreditation (AHCTA), 168
Allowash®, 86, 90, 102, 260
American Association of Tissue Banks (AATB), 4
coding/traceability, 170–1
contamination control, 105, 106
educational programs, 184–6
heart valves, 199
K2.210 standard, 256
microbiological surveillance, 15–16
musculoskeletal tissues, 253, 255, 256, 257–8
skin, 221
American National Standards Institute (ANSI) standard, 259

© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
American Society for Reproductive Medicine (ASRM), 307
amniotic membranes, 22, 59–60, 80, 322
Amsterdam, Treaty of (Article 152), 3
anatomy
  conjunctiva, 233
  cornea, 230–2
  limbus, 233–4
  sclera, 232–3, 249
anionic detergents, 210–11
  see also detergents
ankle joints, 265
annualized rate of occurrence (ARO), 37
ANSI (American National Standards Institute) standard, 259
anti-lymphocyte globulin (ALG), 284
anti-thymocyte globulin (ATG), 284
antibiotic soaks, 198, 202, 205–6
antigen-presenting cells (APC), 313
antigenicity, bone grafts, 87, 99
ANVISA (Agência Nacional de Vigilância Sanitária, Brazil), 7, 8
aorta/aortic valves, 197–8, 204, 207, 208, 213
APC (antigen-presenting cells), 313
aqueous solution processing, 86, 87–91, 93–5, 98–9
ARO (annualized rate of occurrence), 37
ARTG see Australian Registry of Therapeutic Goods (ARTG)
articular tissues
  biomechanical testing, 153–4
  cartilage (hyaline)
    Clostridium infection, 51–2
    culture, 101–2, 320–1
decellularization, 101
donations, 254
hydraulic function, 102
osteochondral grafts, 252–68
processing, 101–2
recovery, 256
clinical uses, 264–5
processing, 261–3
aseptic technique, 107
clean rooms, 115, 116
musculoskeletal tissue retrieval, 65–6
ocular tissue removal, 235–7, 249
skin draping, 57, 58, 59
Asia-Pacific region, 194–5
ASRM (American Society for Reproductive Medicine), 307
asset value (AV), 37
assisted reproductive technology (ART), 80–1, 82, 293–307
Association for the Advancement of Medical Instrumentation (AAMI), 130, 259
ASTM Standard F2077, 150
ATG (anti-thymocyte globulin), 284
ATMP (advanced therapy medicinal products), 10, 11–12, 275, 276–7
ATP (Advance Tissue Process), 260
Australia, 5–6
Australian Registry of Therapeutic Goods (ARTG), 6
authorization/consent, 46–7, 61–2
autologous HSC-A, 283–4
autologous HSC-M, 280–3
automated microkeratome systems, 246–7
AV (asset value), 37
azoospermia, 298
barcodes, 166, 167, 170
Barrett-Boyes, Sir Brian, 198
basis of design (BOD) document, 113
batched blood products, 174
beads, calcium alginate, 76
bicuspid aortic valves, 315
biochemical characterization, 153
BioCleanse® Process, 86, 91, 102, 260
biocompatibility, 156–60
Bioland/Biobank, France, 86, 92, 93, 96, 97, 100
bioengineered tissue replacements see tissue-engineered substitutes
biomechanical characteristics
  see also mechanical stimuli
musculoskeletal tissues, 107
  bone grafts, 100, 101, 150–3, 319
testing, 148–56
membrane tissues, 154–6
methods, 150–6
relevance, 148–9
biopsy, 50, 300
bioreactors, 322–3, 324
biosafety see disease transmission risk
Blood Marrow Transplantation journal, 74
blood products
ABO compatibility, 62, 278, 280
cord blood banking, 63–4, 284
ISBT 128 standard, 161, 168, 169, 171, 173, 175–6, 177
labeling, 174
living donation, 60, 61
samples
cord blood collection, 63–4
decedent donors, 48–50
peripheral blood stem cell collection, 63
BMP (bone morphogenetic proteins), 318
BMVSR (bone mass to volume of solution ratio), 91
BOD (basis of design) document, 113
bone, 252–68
biomechanics, 100, 101, 107, 150–3, 319
cellular matrixes, 266–7
Clostridium infections, 51–2
decedent donor retrieval, 65–6
decellularization case study, 312–3
demineralization, 258, 318, 319, 323
disease transmission risk, 98–9
hematopoietic stem cells collection, 61–4
history
donations, 253, 254
process development, 87–93
injectable putty, 21
intellectual property rights, 86
marrow
collection, 63
HSC-marrow, 27, 272, 273, 278–80, 283
transplantation history, 272–3
microbiological surveillance, 98–9, 142–5
osteocconductivity, 100
osteoinductivity, 263–4, 266, 268, 318
processing, 85–103
aqueous solution processing, 86, 87–91, 93–5
supercritical fluid processing, 86, 91–3, 96–8
efficacy, 100
types of processed bone, 264
structure, 313
bone mass to volume of solution ratio (BMVSR), 91
bone morphogenetic proteins (BMP), 318
borderline products, 13
Brazil, 7–8
BSE (bovine spongiform encephalopathy), 92
buffy coat preparation, 278, 279, 280
burns, 225, 227, 312, 319–20
Burwell, Geoffrey, 311, 313, 318
calcium alginate beads, 76
Canada, 7
cancer, 21, 50, 280, 304
 capacitation, sperm, 298
carbon dioxide, liquid, 86, 96, 97
cardiac tissue, 197–214
 cardiectomy, 201–2
cryopreservation, 80
donor selection criteria, 200–1
enzyme-based decellularization, hypotonic lysis, 209–10
myocardium, 208
processing, 101, 202–12
retrieval techniques, 66–7
risk assessment, 129
valves
decellularization, 208–9, 314–7
future processing, 208–12
history, 198–200
indications for use, 197–98
pulmonary, 197, 204, 207, 213
quality requirements, 204–5
worldwide banking, 212–13
cardiectomy, 201–2
Index

cartilage
  articular (hyaline), 252–68
  Clostridium infection, 51–2
cultured, 320–1
decellularization, 101
donations, 253, 254
  hydraulic function, 102
  processing, 101–2
  recovery, 256
history of donations, 253, 254
vitrification, 76
case studies
  Clostridium infections, 51–2
coding/traceability, 173–7
contamination control, 107–8, 109, 118–19
cultured tissues, 320–1
decellularization, 312–3, 314–7
  Elizabethkingia meningoseptica
  transmission, 118–19
NHSBT Tissue Services, Liverpool, 68–9, 173–4
  Ochrobactrum anthropi meningitis, 107–8
Polish coding system, 175–6
risk management, 35–6
statutory regulations, 20–3
UMC Utrecht coding system, 176–7
CBER (Center for Biologics Evaluation and Research), 4, 14
CD34+ enrichment, 285–6
CDRH (Center for Devices and Radiological Health), 4, 14
cell culture see cultures of cells
cell passaging, 289
cell recovery see tissue and cell recovery
cell transplant products
  ATMP regulation, 276–7
coding/traceability, 171–2, 176–7
donor selection, 277–8
HSC-A, 283–4
HSC-M, 278–3
  list of those in use, 272
non-T-cell therapeutic cell products, 288–90
nonhematopoietic therapeutic cells, 290
open/closed processing, 274
regulatory environment, 274–6
T-cell depletion, 284–6
terminology, 273
therapeutic lymphocyte products, 286, 287, 289
transplantation, processing for, 271–91
cell viability, 222, 244, 249, 263, 310–2
cells and tissue-based therapies (CTT, Singapore), 9
cellular matrices, bone, 266–7
CEN/ISSS Workshop on Coding of Information and Traceability of Human Tissues and Cells, 167–9
Center for Biologics Evaluation and Research (CBER), 4, 14
Center for Devices and Radiological Health (CDRH), 4, 14
centrifugation, bone, 90–1, 92, 94, 278, 279, 280
certification, staff training, 195
cGMP (current Good Manufacturing Practice), 30, 110, 276
CGTP (Current Good Tissue Practice, 2004, US), 4, 16
change control, 136–7
child donors, deceased, 54
Chlamydia trachomatis, 304
chlorhexidine solution, 219
chondrocytes, cultured, 320–1
Chryseobacterium meningosepticum
  (Elizabethkingia meningoseptica), 118–19
CJD (Creutzfeldt–Jakob disease), 35–6, 57
classification
  see also terminology
clean rooms, 110–12
products, 14–15
clean rooms
  cleaning agents, 120, 121
  cleaning procedures, 119–22
  cleaning schedule, 121
  contamination control, 108, 109–15
daily practice, 115–16
definition of clean, 120
design phase, 110–12
engineering study, 122
lifecycle phases, 109–15
monitoring, 117–18
musculoskeletal tissue, 257
necessary attributes, 109–10
operation phase, 115
validation, 112–15
Cleartant Process®, 261
clinical outcomes, bone grafts, 101
clinical uses, bone/soft tissue, 263–5
closed processing, 274
Clostridium infections, 51–2
clothing
deceased donor
in coffin, 47
documentation, 64
gown changes, 58, 115, 116
CMV (cytomegalovirus), 62, 287, 294
COC (cumulus–oocyte complexes), 298
coding/traceability, 161–78
agreed nomenclatures, 165–6
case studies, 173–7
definition, 162
differences between, 163
donor tissues/documentation, 59
EU CEN project, 167–9
gamete/embryo collection, 295–6
global trends, 164–5
harmonization, 171–2
importance, 162–3
machine-readability vs. manual transcription, 166–7
North America, 169–71
principles, 165
systems implementation, 172–3
collagen, 231, 232–3
combination products, 15, 318–9
commensal organisms, 106–7, 140
compact discs for training, 185
competences/expertise required, 187–8
compliance
1-10-100 rule, 36
coding/traceability, 164
performance qualification, 113, 114, 115
process validation, 124–46
regulatory, 19
risk management, 30
composite grafts, 321–2, 324
conduit diameter, 315, 316
conduit tissue decellularization, 208, 211
conjunctiva, 233, 247
consensus, regulatory, 17–18, 21, 22, 165–6, 167–9
consent/authorization, 46–7, 61–2
contamination
see also airborne particles; sterilization
351 products, 15–16
control, 105–22
case studies, 107–8, 109, 118–19
overview, 106–9
recovery environment, 55–9
ocular cultures, 243, 244
tissue recovery techniques to avoid, 57–9
controlled-rate freezing, 282–3
conventional cryopreservation, 75–6
conventional tissue, 5
cooling see cryopreservation; refrigeration
cord blood donors, 62–4, 284
core temperature, 140–2
corneal reflex test, 234
corneas
endothelium, 231, 232, 244, 249
epithelium, 230, 231–2, 249
storage, 242–5
stroma, 230
transplantation, 229–50
vitrification, 76
corneoscleral buttons, 237, 241
corneoscleral rim excision, 236–7, 238
costs, 108, 213, 248
Council of Europe, 2–3
CPAs see cryoprotectant additives (CPAs)
creeping substitution, 313
Creutzfeldt–Jakob disease (CJD), 35–6, 57
cross-contamination see contamination; sterilization
cryopreservation, 71–82
assisted reproductive technology, 80–1, 82
autologous HSC-M, 281–2
cooling, 74–5
decellularized tissues, 79–80, 82
embryos/gametes, 301–2
freeze drying, 78–9
heart valves, 199, 206
infected gamete samples, 295

oocytes, 81, 302

ovarian tissue, 304

recalcitrant tissues, 76

skin, 221–2, 224

sperm, 302–3

vitrification, 75–8

warming, 75

cryoprotectant additives (CPAs)

actions, 301

assisted reproduction, 301

autologous HSC-M, 281–2, 283

Lovelocks list of requirements, 72

overview, 72–4

skin processing, 222

stepwise addition, 73, 77

CTO regulations, Canada, 7

CTT (cells and tissue-based therapies, Singapore), 9

culture strips/plates, clean room monitoring, 117–18

culture-negative sterility concept, 98

cultures of cells

see also organ culture

bioreactors, 322–3, 324

chondrocytes, 320–1

mesenchymal stem cells, 288–9

musculoskeletal tissues, 256

preimplantation development, 299–300

preprocessing, 67

regulation, 11–12

scleral rim, 243

skin, 320

cumulus–oocyte complexes (COC), 298

Current Good Tissue Practice (CGTP, 2004, US), 4, 16

cyclic positive/negative pressure

BioCleanse® Process, 86, 91, 102, 260

bone graft cleansing, 91, 95

cytokine/decellularized matrix combinations, 318–19

cytomegalovirus (CMV), 62, 287, 294

daily practice, clean rooms, 115–16

data see documentation/data

DAVA (decellularized aortic valve grafts), 314, 316–17

DBM (demineralized bone matrix), 318, 319, 323

DC (dendritic cells), 289

DDF (dedicated donation facilities), 68

d-e-epidermized dermis (DED), 222–3, 224

deceased donation

body cooling requirements, 51–2

consent/authorization, 46–7

donor suitability activities, 45–54

infectious disease testing, 48–50

medical records review, 47–8

physical assessment, 52–4

skin preparation/draping, 64

sources, 45–6

test sample collection, 48–51

tissue and cell recovery, 64–8

transport process validation example, 140–2

decellularized aortic valve grafts (DAVA), 314, 316–17

decellularized pulmonary valve allografts (DPVA), 314, 316

decellularized tissues, 312–18

cardiovascular, 101, 208–9

aortic valves, 314, 316–17

cryopreservation, 79–80, 82

skin, 102

decantion see sterilization

DED (de-epidermized dermis), 222–3, 224

dedicated donation facilities (DDF), 68

demineralized bone matrix (DBM), 258, 266, 318, 319, 323

demographics, 46

dendritic cells (DC), 289

dermis see skin

Descemet’s membrane–endothelium complex, 229, 231, 238, 240, 250

design phase, clean rooms, 110–12

detergents

Advance Tissue Process, 260

BioCleanse® Process, 86, 91, 102, 260

bone graft cleansing, 90, 91, 93, 95

cardiac tissue decellularization, 210–11

clean rooms, 120, 121
dextrans, cornea storage, 242, 244
DG SANCO Expert Working Group dataset, 168
dignity, deceased donor, 47, 67–8
dimethyl sulfoxide (DMSO)
  autologous HSC-M, 281, 282
  characteristics, 72, 74, 77
  heart valves, 199, 206
  skin preservation, 222
Directives
  see also European Union
  2001/83/EC, 275
  2004/23/EC
    ATMP regulation, 276
    coding/traceability, 165
    compliance, 9
    donor selection standards, 277
    entry into force, 3
    equipment/process validation, 125
    history, 275
    Poland case study, 175
    reproductive cells, 294
    staff training, 189
  2006/17/EC
    ATMP regulation, 276
    coding/traceability, 165
    donor selection standards, 277
    entry into force, 3
    history, 275
    Poland case study, 175
    reproductive cells, 294
    risk management, 30
  2006/86/EC
    ATMP production, 276
    compliance, 9
    contamination, 106
    donor selection standards, 277
    entry into force, 3
    equipment validation, 124, 125
    history, 275
    Poland case study, 175
    reproductive cells, 294
  2204/23/EC, 106
Clinical Trials Directive, 275
Medical Device Directives, 13
reproductive cells directives, 293–4
disease transmission risk
  assisted reproduction, 294–6, 298, 300, 303
  bone grafts, 87, 98–9
  musculoskeletal tissues, 255
  skin, 217, 225
disinfectants, 120, 121
  see also sterilization
  disposable instruments/equipment, 56–7
dissection technique, cardiectomy, 202
distribution methods, skin, 224–5
DLI (donor lymphocyte infusions), 273
DMSO see dimethyl sulfoxide (DMSO)
DNA/RNA, cardiac tissue, 210, 211
documentation/data
  cardiac tissue, 206
  clean rooms, 109
  cleaning procedures, 119, 121
  coding/traceability, 161–78
deceased donation
  clothing, 64
  funeral, 68
  hearts collected worldwide, 212
  physical assessment, 52
  review, 47–8
  tissue recovery process, 58
  traceability, 59
gamete/embryo collection, 295–6
historical/published, 73, 126, 136
IVF laboratories, 297–8
referral information, 45–6
risk assessments, 34
skin processing, 220, 221
statutory regulations implementation/practice, 17–18
validation/qualification, 125
donated tissues see deceased donation;
  living donation
donor lymphocyte infusions (DLI), 273
donor selection/suitability
  activities to determine, 45–54
  cell transplant products, 62–3, 277–8
  corneas, 232, 246
  exclusion criteria, 21
  heart valves, 200–1
  musculoskeletal tissues, 154, 255, 262
  skin, 217
DPVA (decellularized pulmonary valve allografts), 314, 316
draping techniques, 57, 58, 59, 64, 235

EBV (Epstein–Barr virus), 285
education see staff training
EF (exposure factor), 37
EG (ethylene glycol), 77
Elizabethkingia meningoseptica, 118–19
embryos see gametes/embryos
end user tracking, 163–4
endonucleases, 210, 211
endothelial ocular tissues, 231, 232, 244, 249
endothelial pump, corneal, 231, 232
engineering
see also tissue-engineered substitutes
clean rooms study, 122
definition, 10, 11
enucleation, eyes, 236
environment for processing see process environment
enzyme-based decellularization, 209
epidermis see skin
episcera, 232, 233
Epstein–Barr virus (EBV), 285
EQSTB (European Quality System for Tissue Banking), 187
equipment
automated microkeratomes, 246–7
cell and tissue recovery, 56–7
clean rooms, 115–16
IVF laboratories, 297
qualification/validation, 124–46
principles, 125–6
skin processing, 221
skin procurement, 218
error, human, 306–7
ESHRE (European Society of Human Reproduction and Embryology), 307
ethical aspects, 103, 140
ethylene glycol (EG), 77
ethylene oxide, 259
EUROCET Registry, 18, 253
European Committee for Standardization (CEN), 167–9
European Health Committee of the Council of Europe, 2–3
European Homograft Bank, 213
European Quality System for Tissue Banking (EQSTB), 187
European Society of Human Reproduction and Embryology (ESHRE), 307
European Union
see also Directives
assisted reproduction, 294
borderline products regulation, 13
CEN project, 167–9
contamination control, 105–6
cryoprotectants guidelines, 74
2004/23, 165
EQSTB training course model, 187
Regulations, 2–3, 9–13
No. 1394/2007, 10, 11, 22, 275–6
EUSTITE project, 19
evaluation of risk, 32–3
ex-vivo T-cell depletion, 285–6
experience learning model, 193
exposure factor (EF), 37
exposure time/temperature, 73
extracellular matrix, 230–1
eye see ocular tissues
eyelid closure, 234
face-to-face TPM courses, 189, 191
FACT/JACIE standards, 176, 177, 273, 277, 287
Failure Modes and Effects Analysis (FMEA), 31–2
Fallot’s tetralogy, 314, 316
fascia lata, 154, 155
femoral head, living donation, 59–60
final disposal information, 164, 166
fish-bone diagrams, 31, 35
FMEA (Failure Modes and Effects Analysis), 31–2
Food and Drug Administration (FDA)
351 products, 14–15
cell transplant products regulation, 275
coding/traceability, 164–5
contamination control, 106
gamete/embryo donation safety, 304
inspections, 19
medical devices classification, 4
musculoskeletal tissues, 253
process validation, 124, 125
semen donors, 294
skin processing regulations, 220
skin procurement regulations, 217, 218
stem cell manufacturing regulation case study, 20
four-strike rule, 200
freeze-drying
bone grafts, 87
skin allografts, 222, 223, 224, 225
technique, 78–9
frequency of revalidation/requalification, 137–8
fresh refrigerated valves, 198
fresh skin allografts, 221–2, 223
Fuch’s dystrophy, 238
funeral services, 47, 67–8
G-CSF (granulocyte colony-stimulating factor), 63
gametes/embryos, 293–307
cryopreservation, 301–2
donation, 303–4
embryo biopsy, 300–1
embryo cryopreservation, 303
embryo transfer, 300
fertility preservation during cancer treatments, 304–5
oocyte handling, 298–9
processing methods, 296–304, 307
sperm handling, 298
genetic screening, 303
giant-cell knee tumors, 265
globulins, 284
glove changes, 58
glucosaminoglycan chondroitin sulfate, 242
glycerol
common use, 74
mechanism of action, 72
skin preservation, 222, 223, 224
sperm cryopreservation, 80
vitrification, 77
glycosaminoglycans, 231
glycerol-preserved allografts (GPA), 221
Good Laboratory Practice (GLP), 134
Good Manufacturing Practice (GMP), 30, 110, 134, 276
Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use (EU Guideline), 30, 110
Good Tissue Practice (GTP), 4, 16
gown changes, 58, 115, 116
GPA (glycerol-preserved allografts), 221
Grade A air environments, 274, 296–7
Grade A/B/C/D clean rooms, 111–12
graft rejection, 310–12
graft-versus host disease (GvHD), 272, 277, 286, 287, 289
granulocyte colony-stimulating factor (G-CSF), 63
grid analysis, 118
growth factor combination products, 318–19
Guidelines For Healthcare Institutions Providing Tissue Banking (Singapore), 9
GvHD (graft-versus host disease), 272, 277, 286, 287, 289
H&E (hematoxylin and eosin stain), 153
handling techniques, 66
hands-on workshops, 185, 186
harmonization, 171–2
hazard identification, 32
HCT (Human Cellular and Tissue Therapies) framework (Australia), 6
HCT/Ps (human cells, tissues, and cellular and tissue-based products, US), 5
head elevation for eye donation, 234, 235
heart see cardiac tissue
hematopoietic stem cells (HSCs)
autologous HSC-M, 280–3
cord blood banking, 284
donor selection, 277
history, 271
HSC-apheresis, 272, 273, 283–4
HSC-marrow, 272, 273, 278–83
processing, 61–4
T-cell depletion, 284–6
hematoxylin and eosin (H&E) stain, 153
hepatitis B/C, 277, 294, 303
high-efficiency particulate air (HEPA) filter system, 295, 297

history
assisted reproduction, 293
bone graft process development, 87–93
cell processing for transplantation, 272–3
graft rejection, 311
heart valves, 198–200
ocular tissue recovery, 229–30
sperm banks, 302–3
statutory regulations, 2–9

HIV (human immunodeficiency virus)
assisted reproduction, 294
bone marrow allografts, 87
gamete/embryo donation safety, 304
stem cell manufacturing regulation case study, 20
US regulation, 4

HLA (human leukocyte antigen), 62, 156, 163, 287–8
homovital valves, 203–4
HSC-apheresis (HSC-A), 272, 273, 283–4
HSC-marrow (HSC-M), 272, 273, 278–83
HTLV-1, 277, 294, 303
human cells, tissues, and cellular and tissue-based products (HCT/Ps, US), 5

Human Cellular and Tissue Therapies (HCT) framework (Australia), 6
human error, 305–6
human leukocyte antigen (HLA), 62, 156, 163, 287–8
Human Tissue Act (2004, UK), 275
Human Tissue Authority (HTA, UK), 275

Human Tissue Intended for Transplantation, 4

hyaline (articular) cartilage
Clostridium infection, 51–2
cultured, 320–1
decellularized, 101
donations, 254
hydraulic function, 102
osteoarthritic grafts, 252–68
recovery, 256
hydraulic function, 102
hydrogen peroxide, 90, 91, 95, 259, 260

hypothermic storage, 242–3, 245
see also refrigeration
hypotonic lysis, 209–10

IAEA/NUS diploma course for Asia-Pacific region, 194–5


ice crystal formation, 72, 74, 75
identification, 29, 161–78

IDMs (infectious disease markers), 62, 277
immune response, graft rejection, 311
immunologically privileged tissues, 311
see also cartilage; corneas
immunomagnetic selection, 285–6

infections
see also disease transmission risk; individual infective organisms
cell donors, 62, 277
deceased donation
Clostridium-infected bone/cartilage, 51–2
disease testing, 48–50
lung to heart transfer of infection, 66
ocular cultures, 243
physical assessment, 52, 53, 54
liquid nitrogen, 78

infectious disease markers (IDMs), 62, 277
informed consent, living donation, 60
infusions, deceased donors, 49, 50
insemination, conventional, 299
in-situ corneoscleral rim excision, 236–7
inspections, 19, 235
installation qualification (IQ) test, 113–14

instruments, 56–7, 130, 235–7, 239–42, 259

intellectual property rights, 86, 87–91

Interim Final Rules (US FDA), 4

International Atomic Energy Authority (IAEA), 194–5

Index

International Organization for Standardization (ISO) guidelines
AAMI/ISO 14160, 130
ISO 10993, 157, 159
ISO 14644, 110
ISO 14644-4641, 118, 296
ISO 31000, 31
international training, 183–4
in-vitro fertilization (IVF), 78, 296–8, 299, 307
in-vitro preimplantation culture, 299
ion fluxes, corneal, 231, 232
ion gradients, 73
IQ (installation qualification) test, 113–14
ISBT 128 international coding system, 161, 168–9, 171–2
case studies, 173, 175–7
ISO see International Organization for Standardization (ISO) guidelines
isolation draping, 57, 58, 59
IVF (in-vitro fertilization), 78, 296–8, 299, 307
job descriptions, 182
joints
see also articular tissues
clinical uses, 264–5
recovery of tissue, 65–6, 256
tissue processing, 261–3
K2.210 AATB standard, 256
keratolimbal allografts, 229, 247
knee joints, 265
labeling, 67
blood products, 174
blood samples, 49
cardiac tissue, 206
cellular therapy products, 171–2, 176–7
DG SANCO Expert Working Group
dataset, 168
gametes/embryos, 306
instruments, 56
liquid nitrogen resistant, 306
living donation, 60
musculoskeletal, 258
right/left, excised bones, 66
skin, 222, 223
sterile label claims, 131
laboratories for IVF, 296–8, 307
laboratory corneal rim excision, 238
lamellar keratoplasty, 245–6, 247, 249
laminar flow cabinets, 237, 274, 295
Langerhans cells, 233
language see terminology
leaflet tissue, decellularization, 208
lesions, malignant/suspicious, 21, 50, 280, 304
Lexer, Erich, 253
licences
see also standards; statutory regulations
ATMP regulation, 276
lifecycle phases, clean rooms, 109–15
ligaments, 118–19, 153–4, 265, 267
light microscopy, ocular tissues, 241–2
limbus, 233–4
lipid removal, bone, 93, 96, 313
liquid carbon dioxide, 86, 96, 97
liquid nitrogen, 78, 199, 306
living donation
bone marrow collection, 63
gametes/embryos, 303–4
informed consent, 60
physical assessment, 60–1
tissue and cell recovery, 59–64
log reductions, 129–31
Lovelock’s list of requirements for cryoprotectants, 72
lymphocytes
anti-lymphocyte globulin, 284
donor lymphocyte infusions, 273
T-cell depletion, 273, 284–6
therapeutic lymphocyte products, 273, 286, 287, 289
Tregs, 289
lyophilization see freeze-drying
McCarey–Kaufmann medium, 230
machine-readable codes, 166–7
malignant disease, 21, 50, 280, 304
manual transcription of codes, 166–7
manufacturers’ validation data, 135, 136
marrow see bone, marrow
Masson’s trichrome, 153
mechanical stimuli, bioreactors, 323
Medawar, Sir Peter, 311
medical assessments, 62
medical devices, 4, 13
medical records see documentation/data
medicinal product definition, 13
melanocytes, 233
membrane tissue biomechanics, 154–6
meningitis, 107–8
meniscal allografts, 265
mesenchymal stem cells (MSC), 272, 288–90
meshed skin grafts, 223
microbiological surveillance
   donated tissues, 106–7
      cardiac, 203, 205, 206–7
musculoskeletal tissues,
      presterilization/predisinfection, 256
ocular tissue cultures, 243
process validation, 127, 142–5
resistant microorganisms, 130, 132, 133
skin
   processing, 222
   procurement, 217
US, 15–16
microorganism panels, 132–3, 143
mitigation of risk, 39–40
MNC (mononuclear cell) separation, 278, 279, 280–1
moist chamber technique, 230
monitoring
   see also microbiological surveillance
      clean rooms, 117–18
monoclonal antibodies (MAbs), 284, 285
monocups, decellularized, 316
mononuclear cell (MNC) separation, 278, 279, 280–1
MSC (mesenchymal stem cells), 272, 288–90
musculoskeletal tissues, 252–68
   current issues, 265–6
   donor selection, 255
   future aspects, 266–7
   history of allografts, 253–4
joints/articular surface clinical uses, 264–5
presterilization/predisinfection cultures, 256
processing, 257–8
recovery, 255–6
retrieval techniques, 65–6
sterilization, 107, 259–61, 268
myocardium, 208
National Blood Service Tissue Bank in Liverpool (UK), 314
National Center for Tissue and Cell Banking (NCTCB, Poland), 175
National Program of Blood and Blood Products (Brazil), 8
National Program of Prevention and Control of Hospital Infections (Brazil), 8
National Referral Centre (NRC) nurses, 68
National Sanitary Surveillance System (SNVS, Brazil), 8
natural killer (NK) cells, 290
Navy Bone Bank, US, 85, 86, 87
NCTCB (National Center for Tissue and Cell Banking, Poland), 175
negative pressure, 94, 102–3
Neisseria gonorrhea, 304
NHSBT Tissue Services, Liverpool, 68–9, 173–4, 253
nitrogen, liquid, 78, 199, 306
NK (natural killer) cells, 290
non-T-cell therapeutic cell products, 288–90
nonconformance, 137
nonhematopoietic therapeutic cells, 290
nonviable airborne particulates, 117, 118, 120
North America, 161, 169–71, 212, 213
see also United States
North American Tissue Technical Advisory Group, 161
NovaSterilis process, 97, 261
NRC (National Referral Centre) nurses, 68
nucleases, 210, 211
nutrient delivery, 322–3, 324
Ochrobactrum anthropi, 107–8
ocular tissues, 229–50
see also corneas
   conjunctiva/limbus, 233–4
evaluation, 238–42
future aspects, 248–9
historical background, 229–30
maintenance before donation, 234–5
processing, 237–8
   particular purposes, 245–8
sclera, 232–3, 249
storage, 242–5
vitrification, 76
oligoasthenozoospermia, 298
online training courses, 183–4, 187–94
oocytes, 81, 298–9, 302
open processing, 274
operation phase, 115
operational qualification (OQ), 113, 114, 115
ophthalmic tissues see corneas; ocular tissues
OQ (operational qualification), 113, 114, 115
organ culture, ocular, 242, 243–5
organ/tissue distinction, 275
osmolality, cryoprotectants, 72, 73, 75
osmotic shock, 75
osteoarticular grafts, 252–68
osteochondral grafts, 252–68
osteoconductivity, 100
osteointegration, 263–4, 266, 268, 318
ovarian tissue, cryopreservation, 304–5
packaging
   retrieved tissue, 67
   cardiac, 206
   musculoskeletal, 258
   skin, 222, 223
Parker, Robert, 212
particles
   airborne
      clean rooms, 108–12, 114, 115, 117
      ISO 14644–4641, 296
musculoskeletal tissue processing,
   257
      open/closed processing, 274
passaging of cells, 289
patches, cardiac, 197
patents, 86, 87–91
PBSCs (peripheral blood stem cells), 63
PEG (polyethylene glycol), 79
penetrating keratoplasty, 229–50
Penicillium spp., 109
performance qualification (PQ), 113, 114, 115
pericardium, 107–8, 154, 155
periodic revalidation/requalification, 137–8
peripheral blood stem cells (PBSCs), 63
personnel see staff
PG (propylene glycol), 72, 77
PGA (polyglycolic acid), 321
phosphate-buffered saline (PBS), 235, 238
physical assessment (donors), 52–4, 60–1
picrosirius red stain, 153
placental tissue, 22
plasma dilution, 49
Poland, 175–6, 189, 191
polyethylene glycol (PEG), 79
polyglycolic acid (PGA), 321
polyvinylpyrrolidone (PVP), 79
Pontifícia Universidade Católica do Paraná (PUCPR, Brazil), 314
positive pressure, 109, 110, 112
positive/negative pressure cycling, 86, 91, 95, 102, 260
posterior lenticules, 237, 241
postmortem interval, 234–5
postprocurement activities, 67–8
povidone-iodine detergent, 218, 219
PQ (performance qualification), 113, 114, 115
preprocessing cultures, 67
preservation see also cryopreservation; refrigeration
   musculoskeletal tissues, 259–61
   ocular tissues, 242–5, 247, 249
   skin, 220–1
pressure cycling, 86, 91, 95, 102, 260
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pressure gradients, 109, 110, 112</td>
<td></td>
</tr>
<tr>
<td>prion testing, 51</td>
<td></td>
</tr>
<tr>
<td>Private Hospitals and Medical Clinics Act (Singapore), 8</td>
<td></td>
</tr>
<tr>
<td>probability see statistical probability</td>
<td></td>
</tr>
<tr>
<td>process characterization, 126</td>
<td></td>
</tr>
<tr>
<td>process environment, 105–22</td>
<td></td>
</tr>
<tr>
<td>case studies, 118–19</td>
<td></td>
</tr>
<tr>
<td>clean room</td>
<td></td>
</tr>
<tr>
<td>daily practice, 115–16</td>
<td></td>
</tr>
<tr>
<td>lifecycle, 109–15</td>
<td></td>
</tr>
<tr>
<td>cleaning procedures, 119–22</td>
<td></td>
</tr>
<tr>
<td>monitoring, 117–18</td>
<td></td>
</tr>
<tr>
<td>overview, 106–9</td>
<td></td>
</tr>
<tr>
<td>skin, 220</td>
<td></td>
</tr>
<tr>
<td>process mapping, 31, 35</td>
<td></td>
</tr>
<tr>
<td>process validation, 124–46</td>
<td></td>
</tr>
<tr>
<td>acceptance criteria, 133–4</td>
<td></td>
</tr>
<tr>
<td>benefits, 126–27</td>
<td></td>
</tr>
<tr>
<td>change control, 136–7</td>
<td></td>
</tr>
<tr>
<td>commercially-available processes, 135</td>
<td></td>
</tr>
<tr>
<td>complexity, 127–8</td>
<td></td>
</tr>
<tr>
<td>conditions, 134–5</td>
<td></td>
</tr>
<tr>
<td>examples of studies, 138–45</td>
<td></td>
</tr>
<tr>
<td>historical data, 136</td>
<td></td>
</tr>
<tr>
<td>log reductions, 129–31</td>
<td></td>
</tr>
<tr>
<td>microbiological quality, 127</td>
<td></td>
</tr>
<tr>
<td>nonconformance, 137</td>
<td></td>
</tr>
<tr>
<td>practical aspects, 131–8</td>
<td></td>
</tr>
<tr>
<td>principles, 125–29</td>
<td></td>
</tr>
<tr>
<td>published data, 136</td>
<td></td>
</tr>
<tr>
<td>responsibility assignation, 136</td>
<td></td>
</tr>
<tr>
<td>revalidation/requalification, 137–8</td>
<td></td>
</tr>
<tr>
<td>risk assessment, 128–9</td>
<td></td>
</tr>
<tr>
<td>sterile label claims, 131</td>
<td></td>
</tr>
<tr>
<td>sterility assurance levels, 129–31</td>
<td></td>
</tr>
<tr>
<td>procurement see tissue and cell recovery</td>
<td></td>
</tr>
<tr>
<td>professional standards, 16–17</td>
<td></td>
</tr>
<tr>
<td>professional training see staff, training</td>
<td></td>
</tr>
<tr>
<td>property rights, 86, 87–91</td>
<td></td>
</tr>
<tr>
<td>PUCPR (Pontificia Universidade Católica do Paraná, Brazil), 312</td>
<td></td>
</tr>
<tr>
<td>pulmonary heart valves, 197, 204, 207, 213</td>
<td></td>
</tr>
<tr>
<td>PULSE database, 173, 174</td>
<td></td>
</tr>
<tr>
<td>pumps</td>
<td></td>
</tr>
<tr>
<td>bioreactors, 322–3</td>
<td></td>
</tr>
<tr>
<td>corneal, 231, 232</td>
<td></td>
</tr>
<tr>
<td>PVP (polyvinylpyrrolidine), 79</td>
<td></td>
</tr>
<tr>
<td>QSR (Quality System Regulations, US), 14</td>
<td></td>
</tr>
<tr>
<td>qualification of equipment see validation</td>
<td></td>
</tr>
<tr>
<td>qualification of staff see staff, training qualified person (QP), 276–7</td>
<td></td>
</tr>
<tr>
<td>Quality System Regulations (QSR, US), 14</td>
<td></td>
</tr>
<tr>
<td>quality of tissues</td>
<td></td>
</tr>
<tr>
<td>cardiac, 204–5</td>
<td></td>
</tr>
<tr>
<td>European Quality System for Tissue Banking, 187</td>
<td></td>
</tr>
<tr>
<td>heart valve donor selection, 200–1</td>
<td></td>
</tr>
<tr>
<td>process validation, 127, 137</td>
<td></td>
</tr>
<tr>
<td>skin, 223–4</td>
<td></td>
</tr>
<tr>
<td>quarantine postprocessing inventories, 223</td>
<td></td>
</tr>
<tr>
<td>radiation</td>
<td></td>
</tr>
<tr>
<td>Allowash-XG®, 86, 90, 102, 260</td>
<td></td>
</tr>
<tr>
<td>bone, 313</td>
<td></td>
</tr>
<tr>
<td>heart valves, 198</td>
<td></td>
</tr>
<tr>
<td>musculoskeletal tissue, 107, 257, 259, 260</td>
<td></td>
</tr>
<tr>
<td>patient conditioning, 284</td>
<td></td>
</tr>
<tr>
<td>sterilization, 107, 198</td>
<td></td>
</tr>
<tr>
<td>radio frequency identification (RFID) tags, 166, 167</td>
<td></td>
</tr>
<tr>
<td>raw materials, clean rooms, 115–16</td>
<td></td>
</tr>
<tr>
<td>recalcitrant tissues, 76</td>
<td></td>
</tr>
<tr>
<td>reconstruction, 67–8, 237</td>
<td></td>
</tr>
<tr>
<td>recovery of tissue see tissue and cell recovery</td>
<td></td>
</tr>
<tr>
<td>reduced intensity conditioning, 284</td>
<td></td>
</tr>
<tr>
<td>referral information see documentation/data</td>
<td></td>
</tr>
<tr>
<td>refrigeration</td>
<td></td>
</tr>
<tr>
<td>see also cryopreservation</td>
<td></td>
</tr>
<tr>
<td>cardiac donors post-death, 201</td>
<td></td>
</tr>
</tbody>
</table>
corneas, hypothermic storage, 242–3, 245
deceased donor bodies, 51–2
skin, 220
vitrification, 77–8
Regulations see European Union, Regulations; statutory regulations
regulatory compliance see compliance
regulatory consensus, 17–18, 21, 22, 165–6, 167–9
regulatory T cells (Tregs), 289
Reisner, Yair, 273
rejection of grafts
graft-versus-host disease, 272, 277, 286, 287, 289
viable allografts, 310–12
research data, 73, 126
resistant microorganisms, 130, 132, 133
retention of risk, 40
retrieval of tissue see tissue and cell recovery
retrospective data, 136
reusable equipment, 57
revalidation, 137–8
RFID (radio frequency identification) tags, 166, 167
rheumatic disease, 315
RICATM (Rotary In Situ Cleaning Apparatus), 261
right ventricular outflow tract (RVOT), 314–16
right/left labeling, excised bones, 66
risk assessment
see also disease transmission risk
deceased donation, 52–4
detectability of risk, 30, 33–4
heart valve donor suitability, 200–1
process validation, 128–9
risk avoidance, 39
risk management, 27–41
application, 34–5
coding/traceability, 161–78
cost aspects, 36–7
definitions, 28, 30
documentation, 34
importance, 29–30
methodologies/tools, 31–4
mitigation of risk, 39–40
ongoing activities, 38–9
principles, 28–9
reasonable care, 27
summary diagram/notes, 38, 40–1
team approach, 37–9
risk matrix, 33
risk priority number (RPN), 34
Ross procedure, 197, 213, 314–16
Ross, Sir Donald, 198, 205
Rotary In Situ Cleaning Apparatus (RICATM), 261
RPN (risk priority number), 34
RVOT (right ventricular outflow tract), 314–16
safety see risk ...
The Safety of Human cells, Tissues and Organs for Transplantation Regulations (CTO regulations, Canada), 7
safranin O staining, 153
SAL see sterility assurance level (SAL)
samples
musculoskeletal tissues, 256
size, 132–3, 151, 152
test sample collection, 48–51, 60, 61, 118
scaffolds, bone, 263–4, 266, 268
clera, 232–3, 247, 249
SDS (sodium dodecyl sulfate), 210, 211, 314
Sell, Dr Kenneth, 184
semen donors, 294
sequencing of tissue recovery, 48, 49, 57
severity of risk, 30, 32–33
sexually transmitted diseases (STDs), 54, 277, 294, 303
shaking/agitation methods, 92, 93, 94
shaving of skin, 218
shoulder joints, 265
Singapore, 8–9, 194, 195
single loss expectancy (SLE), 37
single-use equipment, 56–7
sink waste trap contamination, 119
site suitability, 55–6
sizing of allografts, 204, 265
skeletal tissue, 252–68
see also bone; musculoskeletal tissue

skin, 217–27

biomechanical testing, 154, 155
burns repair requirements, 312
cultured, case study, 320
deceased donor, retrieval techniques, 65
distribution, 224–5
draping techniques, 57, 58, 59, 64, 235
function, 319
future aspects, 226
indications for use, 225–6
living donation, 59–60
processing, 102, 219–23
procurement, 217–19
quality control tests, 223–4
transportation process validation, 138–40

SLE (single loss expectancy), 37
slit-lamp eye examination, 236, 239–40
slow freezing, 75–6
SNVS (National Sanitary Surveillance System, Brazil), 8
sodium dodecyl sulfate (SDS), 210, 211, 314
solutions for processing, 107–8
South America, staff training, 186–7
Spain, 183–4, 186, 187–94, 253
specialist nurses, 48, 68
specifications, clean rooms, 113
specular microscopy, 240–1
spermatozoa, 80–1, 298, 302–3
spore-bearing microorganisms, 132, 133

staff

responsibility assignation, 136
risk management team approach, 37–9
training, 180–96
AATB educational programs, 184–6
certification, 195
clean rooms, 108, 110, 115–16
deceased donation
medical records review, 47
physical assessment, 53
EQSTB course model for EU countries, 187
gamete/embryo collection, 305
IAEA/NUS diploma course for Asia-Pacific region, 194–5
international experience, 183–4
living donation, 60
needs, 182–3
skin procurement, 217–18
South America, 186–7
TPM international on-line/face-to-face training, 183–4, 187–94

staining methods, 153
standard operating procedures (SOPs)
clean rooms, 109, 114, 115, 116
tissue recovery documentation, 59
training, 306
vCJD-infected tissues case study, 35–6

standards
see also standard operating procedures (SOPs); statutory regulations
AATB musculoskeletal tissue standards, 255, 256, 257–8
assisted reproduction, 307
ASTM Standard F2077, 150
biocompatibility, 156–8
cell transplant product terminology, 273
clean rooms design phase, 110–12
coding/traceability, 161–2, 164–5
FACT/JACIE standards, 176
contamination control, 105–6
cryoprotectants, EU guidelines, 74
gametes/embryos collection/processing, 293
hematopoietic stem cells collection, 61
ISBT 128 standard, 168, 169, 171, 173, 175–6, 177
ISO 10993, 157, 159
ISO 14644, 110
ISO 14644–4641, 118, 296
ISO 31000, 31
musculoskeletal tissues, sterilization, 259
professional, 16–17
skin procurement, 217, 218
staff training, 181
Staphylococcus epidermidis, 243
starch-containing cryoprotectants, 281, 282, 283
statistical probability
risk assessment, 32, 33, 37, 128–9
sample size, 151
sterility concept, 98, 99
statutory regulations, 1–23
see also Directives
Australia, 5–6
Brazil, 7–8
Canada, 7
case studies, 20–3
cell transplant products, 274–6
Europe, 2–3, 9–13
gamete/embryo collection, 306
history of development/scope, 2–9
implementation/practice, 17–19
musculoskeletal tissue sterilization, 259
musculoskeletal tissues, 265, 266
professional standards role, 16–17
Singapore, 8–9
skin processing, 220
skin procurement, 217, 218
United States, 3–5, 14–16
stem cells, 20
see also hematopoietic stem cells (HSCs)
stepwise addition of cryoprotectants, 73, 77
sterilants, 120, 121, 130, 198
sterility, 78, 131, 134, 274
technique see aseptic technique
sterility assurance level (SAL)
aqueous solution processing, 98, 99
musculoskeletal tissue processing, 258, 259, 260
process validation, 129–31
sterilization
see also radiation
bone grafts, 85–103
clean rooms design, 112
eyes, 238
heart valves, 198
musculoskeletal tissue, 257–8, 259–61, 268
radiation, 107
reusable instruments/equipment, 57
skin
processing, 220–1
procurement, 218–19
terminal, 112, 134, 259
storage see cryopreservation; preservation;
refrigeration; vitrification
stress forces, bioreactors, 323
suitability of donors see donor selection/
suitability
supercritical carbon dioxide, 92–3, 100, 259, 260
supercritical fluid processing, 86, 91–3, 96–8, 100
swinging microkeratomes, 246–7
symbols, coding, 166
syphilis, 277, 294
T cells
depletion (TCD), 273, 284–6
donor lymphocyte infusions, 273
TC-T, 273, 286, 287
Tregs, 289
TAP (Tissue Action Plan), 4
TBV (total blood volume), 49, 50
TC-T (therapeutic cells-T cells), 273, 286, 287
TCD (T cell depletion), 273, 284–6
TE (tissue establishments), 2, 12, 68–9
team approach, 37–9, 256
TEBVs (tissue-engineered blood vessel), 77
tendons/ligaments, 118–19, 153–4, 265, 267
Tenon’s capsule, 232, 233
terminal sterilization, 112, 134, 259
terminology
appropriate, 2
cell transplant products, 273
coding/traceability, 161–2, 165–6, 171–2, 173, 177
consecutive/cumulative distinction, 36
meaning of ‘sterile’, 131
sterility assurance/log reductions, 129–31
validation/qualification, 124, 125, 126
TEST egg yolk buffer (TYB), 80
test sample collection, 48–51, 60, 61, 118
testicular sperm aspiration (TESA), 298
testicular sperm extraction (TESE), 298
testing procedures
biocompatibility, 156–60
biomechanical characteristics, 148–56
process validation, 124–46
tetralogy of Fallot, 314, 316
tetrazolium salt assay, 222
TGA (Therapeutic Goods Administration, Australia), 5, 6
TGF-β (transforming growth factor β), 318
therapeutic cells-T cells (TC-T), 273, 286, 287
Therapeutic Goods Act 1989 (Australia), 5
Therapeutic Goods Administration (TGA, Australia), 5, 6
timing of skin procurement, 218–19
Tissue Action Plan (TAP), 4
Tissue Banking for Transplantation (Sell & Friedlander, 1976), 85
Tissue and Cell Directives see European Union, Directives
tissue and cell recovery, 44–69
decedent donation
cardiac tissue, 201–2
donor suitability activities, 45–54
environment, 55–6
model, 68–9
musculoskeletal tissue, 256
procurement preparations, 55–9
recovery model, 68–9
skin, 217–19
techniques, 57–9, 64–8
living donation
gametes/embryos, 293–307
hematopoietic stem cells, 61–4
mesenchymal stem cells, 289
skin/amniotic membrane/femoral head, 59–61
tissue establishments (TE), 2, 12, 68–9
tissue loss case study, 109
Tissue Reference Group (TRG, FDA), 14
tissue-engineered blood vessel (TEBVs), 77
tissue-engineered substitutes, 76–7, 310–24
bioreactors, 322–3, 324
blood vessels, 77
cells/matrices, 321–12, 324
cytokine/decellularized matrix combinations, 318–19
decellularization of tissue allografts, 312–8
viable allografts, acute rejection, 310–12
total blood volume (TBV), 49, 50
total plasma volume (TPV), 49, 50
TPM (transplant procurement manager) training, 183–4, 187–94
TPV (total plasma volume), 49, 50
traceability see coding/traceability tracking, 162, 163–4
training see staff training
transfer of risk, 39
transforming growth factor β (TGF-β), 318
translation tables, 166
transmission of disease see disease transmission risk; risk assessment
transparency, 35
transplant procurement manager (TPM) training, 183–4, 187–94
Transplant Services Foundation, Spain, 253
Transplantation Transmission Sentinel Network (TTSN), 170
transport, 67, 138–42
trauma, 53, 54, 57, 58, 59
Treaty of Amsterdam, Article 152, 3
Tregs (regulatory T cells), 289
TRG (Tissue Reference Group, FDA), 14
Trinity Evolution®, 266
truth concept, science/patents, 86–7
Trypanosoma cruzi, 294
TTSN (Transplantation Transmission Sentinel Network), 170
tumors, malignant/suspicious, 21, 50, 280, 304
TYB (TEST egg yolk buffer), 80
ultrasonic cavitation, 90, 95
umbilical cord donors, 62–4, 284
UMC Utrecht, 176–7
uniqueness of grafts, 162–3, 165, 166–7, 170–1
United Kingdom, 275
United States
see also American Association of Tissue Banks (AATB); Food and Drug Administration (FDA)
assisted reproduction, 294
cell transplant products, 275
Code of Federal Regulations (CFR) 21, Parts 1270/1271, 4–5
coding/traceability, 169–71
heart valve banking, 212, 213
musculoskeletal tissues regulation, 265, 266
process validation, 124
statutory regulations, 3–5, 14–16
US Navy Bone Bank, 85, 86, 87
Urist, MR, 318
US Navy Bone Bank, 85, 86, 87
user requirement specifications (URS), 113
validation, 112–15, 121, 258
see also process validation
valves see cardiac tissue, valves
van Geison and Verhoeff (VVG) stain, 153
variant Creutzfeldt–Jakob disease (vCJD), 35–6
viability of cells, 222, 244, 249, 263, 310–12
viable microorganisms, 117–18, 120
virus inactivation, 100
vitrification, 75–8
addition/removal of vitrification solution, 77
cooling/warming rates, 77–8
process description, 301
sterility, 78
tissue-engineered substitutes, 76–7
volume preservation, 100
volume reduction, 278, 280
VVG (van Geison and Verhoeff stain), 153
warm ischemic time, 199
warming, 75, 78
waste traps contamination, 119
water loss, epidermis, 319
Web-based training, 183–5, 187–94
wet workshops, 185
wet-stored valves, 198
witnessing, 306
workshops, staff training, 185, 186
World Congress of Tissue Banks, 212
World Health Assembly, 161, 172–3
World Health Organization (WHO), 2
World Marrow Donor Association (WMDA), 164–5
Yacoub, Professor Sir Magdi, 199, 203, 205
zone recovery techniques, 57–8, 59